T. Rowe Price reports 11.8% Karyopharm Therapeutics (KPTI) stake

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 2,244,421 shares of THERAPEUTICS INC common stock, representing 11.8% of the class as of the event date December 31, 2025.

The firm reports sole voting and dispositive power over 1,491,409 shares and no shared voting or dispositive power. It states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, and expressly denies beneficial ownership beyond what is required to be reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 10:28 AM Learn about SEC filing dates

FAQ

How many KPTI shares does T. Rowe Price Investment Management report owning?

T. Rowe Price Investment Management reports beneficial ownership of 2,244,421 shares of THERAPEUTICS INC common stock. This stake represents a significant holding and triggers the requirement to file a Schedule 13G/A with detailed ownership and voting power information.

What percentage of KPTI’s common stock does T. Rowe Price Investment Management hold?

T. Rowe Price Investment Management reports owning 11.8% of THERAPEUTICS INC common stock. This level of beneficial ownership crosses the 5% reporting threshold, requiring public disclosure of its position and associated voting and dispositive powers under Schedule 13G rules.

How much voting power does T. Rowe Price Investment Management have over KPTI shares?

The firm reports sole voting power over 1,491,409 shares of THERAPEUTICS INC common stock and no shared voting power. It also reports sole dispositive power over the same number of shares, indicating it alone can decide how those shares are voted and disposed.

Is T. Rowe Price Investment Management seeking to influence control of KPTI?

The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of the issuer. It further notes that the position is not held in connection with any control-related transaction or similar arrangement.

What type of SEC filing did T. Rowe Price Investment Management submit for KPTI?

It submitted an Amendment No. 2 to Schedule 13G for THERAPEUTICS INC common stock. Schedule 13G is used by certain institutional investors to report beneficial ownership positions when securities are held for investment purposes rather than to influence control.

When was the ownership position in KPTI measured for this Schedule 13G/A?

The reported ownership position is measured as of December 31, 2025, identified as the date of the event requiring the filing. This date anchors the 2,244,421 shares and 11.8% beneficial ownership disclosed in the Schedule 13G/A amendment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

KARYOPHARM THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

48576U205

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 48576U205

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,491,409.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,491,409.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,244,421.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KARYOPHARM THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA, 2459
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 48576U205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2244421
(b)	Percent of class: 11.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1491409
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1491409
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	02/17/2026